IDP-126 Gel Shows Promising Results In Moderate-to-Severe Acne Treatment

A poster presentation at Winter Clinical Miami 2023 in Miami, Florida observed the reduction in moderate-to-severe acne with IDP-126 gel (Epiduo Forte) compared to its dyads and vehicle gel treatments.¹ The gel in trials was a first-ever triple-combination, fixed-dose acne topical consisting of clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15 gel. Many acne medication regimens on the market may take weeks or months to show substantial results patients notice and will continue using. Studies among patients aged 9 and older showed therapeutic effects of IDP-126 gel were rapid and sustained.

Frank29052515/AdobeStock

Patients enrolled in phase 2 (n=741) and 3 (n=183) studies of the gel were enrolled for 12 weeks. They were randomized to receive one daily treatment of IDP-126 or vehicle gel. The phase 2 study included 3 additional dyad gel randomization arms BPO/adapalene, clindamycin phosphate/BPO, and clindamycin phosphate/adapalene. Researchers assessed the percentage of study participants achieving ≥33%, ≥50%, and ≥75% thresholds in lesion reduction over the 12-week study period.

The results of the IDP-126 gel use showed promising, accelerated results compared to other topical acne treatments on the market prior to the study. Lesion count reductions were greater with IDP-126 versus the dyads and vehicle gel as early as week 4 with a majority of study participants seeing substantial reductions at 12 weeks and beyond. During phase 3 trials, almost 80% of patients achieved one-third reduction in inflammatory lesions. The same number of study participants saw gradual and maintained improvement with a 50% reduction in inflammatory lesions at weeks 8 and 12. Nearly 70% of participating patients saw more than three-fourths reduction in inflammatory lesions at the week 12 check in.

The fast-acting features of IDP-126 offered an antibiotic, antibacterial, and retinoid in 1 once-daily application. Researchers believe the efficacy shown in the study may positively impact treatment adherence in acne patientslong-term.

Reference

1. Harper J,Kircik L, Gold M, et al. Early and sustained reductions in moderate-to-severe acne with fixed-dose clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15 gel. Poster presented at: Winter Clinical Miami 2023; February 17-20, 2023. Miami, FL